Talphera, Inc. (NASDAQ:TLPH) Sees Large Decline in Short Interest

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 30,500 shares, a decline of 49.0% from the December 15th total of 59,800 shares. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are sold short.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new position in shares of Talphera, Inc. (NASDAQ:TLPH) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises approximately 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest position. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent quarter. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Maxim Group raised Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Performance

Shares of TLPH stock opened at $0.58 on Tuesday. The company has a market capitalization of $9.81 million, a price-to-earnings ratio of -0.84 and a beta of 0.28. Talphera has a 52 week low of $0.50 and a 52 week high of $1.61. The company has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.83.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.